The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 Apr 2019
Historique:
received: 13 02 2019
revised: 28 03 2019
accepted: 30 03 2019
entrez: 4 4 2019
pubmed: 4 4 2019
medline: 16 7 2019
Statut: epublish

Résumé

Cancer is one of the most diagnosed diseases in developed countries. Inflammation is a common response to different stress situations including cancer and infection. In those processes, the family of mitogen-activated protein kinases (MAPKs) has an important role regulating cytokine secretion, proliferation, survival, and apoptosis, among others. MAPKs regulate a large number of extracellular signals upon a variety of physiological as well as pathological conditions. MAPKs activation is tightly regulated by phosphorylation/dephosphorylation events. In this regard, the dual-specificity phosphatase 10 (DUSP10) has been described as a MAPK phosphatase that negatively regulates p38 MAPK and c-Jun N-terminal kinase (JNK) in several cellular types and tissues. Several studies have proposed that extracellular signal-regulated kinase (ERK) can be also modulated by DUSP10. This suggests a complex role of DUSP10 on MAPKs regulation and, in consequence, its impact in a wide variety of responses involved in both cancer and inflammation. Here, we review DUSP10 function in cancerous and immune cells and studies in both mouse models and patients that establish a clear role of DUSP10 in different processes such as inflammation, immunity, and cancer.

Identifiants

pubmed: 30939861
pii: ijms20071626
doi: 10.3390/ijms20071626
pmc: PMC6480380
pii:
doi:

Substances chimiques

DUSP10 protein, human EC 3.1.3.16
Mitogen-Activated Protein Kinase Phosphatases EC 3.1.3.16
Dual-Specificity Phosphatases EC 3.1.3.48

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Ciencia e Innovación
ID : SAF-2013-42850-R
Organisme : Ministerio de Ciencia e Innovación
ID : SAF2016-75988-R
Organisme : Comunidad de Madrid
ID : S2017/BMD-3671
Organisme : Fondo de Investigaciones Sanitarias
ID : BIOMID
Organisme : Fundación Científica Asociación Española Contra el Cáncer
ID : AECC-AIO

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Biol Chem. 1999 Jul 9;274(28):19949-56
pubmed: 10391943
Oncogene. 1999 Nov 25;18(50):6981-8
pubmed: 10597297
Cytogenet Cell Genet. 2000;90(1-2):71-4
pubmed: 11060451
J Biol Chem. 2002 Aug 30;277(35):31818-25
pubmed: 12082107
Nature. 2004 Aug 12;430(7001):793-7
pubmed: 15306813
J Steroid Biochem Mol Biol. 2004 Oct;92(3):131-41
pubmed: 15555907
Cancer Res. 2006 Apr 15;66(8):4516-24
pubmed: 16618780
J Mol Biol. 2006 Jul 28;360(5):946-55
pubmed: 16806267
J Immunol. 2006 Dec 1;177(11):7497-504
pubmed: 17114416
Carcinogenesis. 2007 Jun;28(6):1188-96
pubmed: 17151092
Protein Sci. 2007 May;16(5):880-6
pubmed: 17400920
Cancer Metastasis Rev. 2008 Jun;27(2):253-61
pubmed: 18330678
J Biol Chem. 2008 May 23;283(21):14277-85
pubmed: 18356163
Exp Cell Res. 2008 Jun 10;314(10):2066-75
pubmed: 18410923
J Biol Chem. 2008 Sep 26;283(39):26591-601
pubmed: 18669639
Mol Cell Biol. 2009 Mar;29(6):1538-53
pubmed: 19139271
Nat Rev Cancer. 2009 Aug;9(8):537-49
pubmed: 19629069
EMBO J. 2009 Oct 7;28(19):2896-907
pubmed: 19696743
Am J Physiol Renal Physiol. 2009 Dec;297(6):F1622-31
pubmed: 19776174
Infect Immun. 2010 Jun;78(6):2454-65
pubmed: 20351145
Cell Oncol. 2010;32(5-6):361-72
pubmed: 20413845
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Biol Chem. 2011 Jun 3;286(22):19605-16
pubmed: 21487011
Cell Signal. 2012 May;24(5):1002-11
pubmed: 22245064
Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L866-74
pubmed: 22307906
Sci Signal. 2011 Dec 20;4(204):pe47
pubmed: 22375047
Sci Signal. 2011 Dec 20;4(204):ra88
pubmed: 22375048
J Biol Chem. 2012 May 18;287(21):17554-67
pubmed: 22467874
Cell Signal. 2012 Oct;24(10):1889-98
pubmed: 22683306
Oncol Rep. 2012 Sep;28(3):931-6
pubmed: 22711061
Cell Commun Signal. 2012 Jul 11;10(1):19
pubmed: 22784513
Exp Mol Pathol. 2012 Dec;93(3):294-301
pubmed: 23018130
Oncogene. 2013 Nov 7;32(45):5302-14
pubmed: 23334324
Med Oncol. 2013 Jun;30(2):517
pubmed: 23440723
J Clin Invest. 2013 May;123(5):2064-77
pubmed: 23543058
Eur J Cancer Prev. 2014 May;23(3):173-6
pubmed: 23872954
Toxicol Appl Pharmacol. 2013 Nov 15;273(1):130-9
pubmed: 23993976
Antioxid Redox Signal. 2014 May 10;20(14):2251-73
pubmed: 24206177
Cell Death Differ. 2014 Mar;21(3):427-37
pubmed: 24270408
Biomed Pharmacother. 2014 Feb;68(1):25-30
pubmed: 24332650
J Immunol. 2014 Apr 15;192(8):3686-96
pubmed: 24634491
Int J Oncol. 2014 Dec;45(6):2250-66
pubmed: 25201346
J Steroid Biochem Mol Biol. 2015 Apr;148:275-82
pubmed: 25448738
Basic Clin Pharmacol Toxicol. 2015 Aug;117(2):96-104
pubmed: 25615285
Oncogene. 2016 Jan 14;35(2):206-17
pubmed: 25772234
Cell Rep. 2015 Mar 17;10(10):1722-1734
pubmed: 25772359
PLoS One. 2015 Apr 13;10(4):e0124339
pubmed: 25875760
J Biol Chem. 2015 Jun 12;290(24):14875-83
pubmed: 25922079
Int J Clin Exp Pathol. 2015 Feb 01;8(2):2018-25
pubmed: 25973098
Mol Oncol. 2016 May;10(5):652-62
pubmed: 26733232
Nat Commun. 2016 Mar 18;7:10879
pubmed: 26988444
J Clin Neurosci. 2016 Aug;30:110-114
pubmed: 27050915
J Orthop Res. 2017 Feb;35(2):331-339
pubmed: 27101204
FEBS J. 2016 Jun;283(11):2197-201
pubmed: 27263510
Phytother Res. 2017 Jul;31(7):1072-1077
pubmed: 28504466
Cancer Res. 2017 Sep 1;77(17):4602-4612
pubmed: 28674078
Elife. 2017 Oct 18;6:
pubmed: 29043977
Environ Toxicol. 2018 Mar;33(3):269-279
pubmed: 29165873
Sci Rep. 2018 Feb 14;8(1):2979
pubmed: 29445242
Oncotarget. 2018 Jan 6;9(5):6391-6401
pubmed: 29464080
Nat Commun. 2018 Oct 12;9(1):4231
pubmed: 30315197
J Virol. 2019 Jan 4;93(2):null
pubmed: 30333178
Inflammation. 2019 Feb;42(1):235-245
pubmed: 30411211
Nucleic Acids Res. 2019 Jan 8;47(D1):D100-D105
pubmed: 30445619
Front Neurosci. 2019 Jan 23;13:16
pubmed: 30728764

Auteurs

Marta Jiménez-Martínez (M)

Department of Cell Biology and Immunology, Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), 28049 Madrid, Spain. mjimenez@cbm.csic.es.
Department of Molecular Biology, Universidad Autónoma de Madrid, 28049 Madrid, Spain. mjimenez@cbm.csic.es.
Instituto de Investigación Sanitaria la Princesa (IIS-P), 28006 Madrid, Spain. mjimenez@cbm.csic.es.

Konstantinos Stamatakis (K)

Department of Cell Biology and Immunology, Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), 28049 Madrid, Spain. kstamatakis@cbm.csic.es.
Department of Molecular Biology, Universidad Autónoma de Madrid, 28049 Madrid, Spain. kstamatakis@cbm.csic.es.
Instituto de Investigación Sanitaria la Princesa (IIS-P), 28006 Madrid, Spain. kstamatakis@cbm.csic.es.

Manuel Fresno (M)

Department of Cell Biology and Immunology, Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), 28049 Madrid, Spain. mfresno@cbm.csic.es.
Department of Molecular Biology, Universidad Autónoma de Madrid, 28049 Madrid, Spain. mfresno@cbm.csic.es.
Instituto de Investigación Sanitaria la Princesa (IIS-P), 28006 Madrid, Spain. mfresno@cbm.csic.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH